Pharmaceuticals 2010, 3(11), 3478-3493; doi:10.3390/ph3113478
Review

Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease

Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, FL 32610, USA
* Author to whom correspondence should be addressed.
Received: 21 September 2010; in revised form: 27 October 2010 / Accepted: 8 November 2010 / Published: 9 November 2010
(This article belongs to the Special Issue GPCR Based Drug Discovery)
PDF Full-text Download PDF Full-Text [307 KB, uploaded 9 November 2010 12:35 CET]
Abstract: Patients with hypertension often manifest a dysregulated renin-angiotensin-aldosterone system (RAAS). Most of the available treatment approaches for hypertension are targeted towards the RAAS including direct renin inhibition, ACE inhibition, angiotensin II type 1 receptor (AT1-R) blockade, and aldosterone receptor antagonism. The Jak2 signaling pathway is intricately coupled to the AT1-R signaling processes involved in hypertension. Here, we review the involvement of Jak2 in the pathogenesis of hypertension, and its potential as a therapeutic target for treatment of AT1-R mediated cardiovascular disease. Jak2 may provide a rational therapeutic approach for patients whose blood pressure is not controlled by standard therapies.
Keywords: angiotensin II; Jak2; AT1-receptor; hypertension

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Kirabo, A.; Sayeski, P.P. Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease. Pharmaceuticals 2010, 3, 3478-3493.

AMA Style

Kirabo A, Sayeski PP. Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease. Pharmaceuticals. 2010; 3(11):3478-3493.

Chicago/Turabian Style

Kirabo, Annet; Sayeski, Peter P. 2010. "Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease." Pharmaceuticals 3, no. 11: 3478-3493.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert